Paid Clinical Trials in Greenwich, CT
As of July 2026, 52 paid clinical trials are recruiting in Greenwich, Connecticut. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Greenwich offers studies at sites including Smilow Cancer Hospital Care Center at Greenwich for conditions such as Anatomic Stage II Breast Cancer AJCC v8, Breast Cancer, Stage IV Lung Cancer AJCC v8, Recurrent Lung Non-Small Cell Carcinoma. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Greenwich
Trials by drug in Greenwich
Filter results
Newly added in Greenwich
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
51 clinical trials
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
Dermal Allograft Augmentation of Large and Massive Rotator Cuff Tears
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Top Research Study Locations in Greenwich
Researchers run research studies in Greenwich, CT at 9 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Smilow Cancer Hospital Care Center at Greenwich | Anatomic Stage II Breast Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Recurrent Lung Non-Small Cell Carcinoma | 39 |
| Coastal Eye Surgeons | Macular Edema Secondary to Inflammation, Geographic Atrophy, Macular Degeneration | 4 |
| Greenwich Hospital | Dupuytren's Contracture, Gynecologic Surgeries, Pelvic Organ Prolapse | 2 |
| Smilow Cancer Hospital - Greenwich | Breast Cancer, Breast Neoplasms | 2 |
| Coastal Eye Surgeons, LLC | DME, Diabetic Macular Edema, Diabetic Macular Edema (DME) | 1 |
| Gandelman Cardiology, PC | Cardiovascular Disease | 1 |
| Orthopaedic & Nuerosurgery Specialists | Full-thickness Rotator Cuff Tear | 1 |
| Smilow Cancer Hospital Care Center - Greenwich | Metastatic Breast Cancer | 1 |
| Yale New Haven Health-Greenwich Hospital | Lumbar Spinal Stenosis | 1 |
Active & Upcoming Studies in Greenwich (2026)
Recruiting trials in Greenwich grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (38 active studies)
- Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial · Phase 3 · NRG Oncology
- ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab · Phase 3 · Alliance for Clinical Trials in Oncology
Eye & vision (5 active studies)
- CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME · Phase 3 · EyePoint Pharmaceuticals, Inc.
- A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK · Phase 3 · Kodiak Sciences Inc
Neurology & pain (1 active study)
- SORE Study: Sitz Baths After Urogynecologic Reconstruction · Yale University
Common conditions studied in Greenwich
- Anatomic Stage II Breast Cancer AJCC v8 (4 active studies)
- Breast Cancer (4 active studies)
- Stage IV Lung Cancer AJCC v8 (4 active studies)
- Recurrent Lung Non-Small Cell Carcinoma (3 active studies)
- Anatomic Stage I Breast Cancer AJCC v8 (2 active studies)
- Anatomic Stage IIIA Breast Cancer AJCC v8 (2 active studies)
Leading research sponsors in Greenwich
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
- NRG Oncology
- Alliance for Clinical Trials in Oncology
- ECOG-ACRIN Cancer Research Group
Frequently asked questions
How many paid clinical trials are currently recruiting in Greenwich?
There are approximately 52 recruiting clinical trials in Greenwich, Connecticut listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Greenwich pay participants?
Most recruiting trials in Greenwich compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Greenwich?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Greenwich?
The most common conditions under active study in Greenwich include Anatomic Stage II Breast Cancer AJCC v8 (4), Breast Cancer (4), Stage IV Lung Cancer AJCC v8 (4), Recurrent Lung Non-Small Cell Carcinoma (3), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Greenwich?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Greenwich on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Greenwich?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Greenwich?
Recruiting research sites in Greenwich include Smilow Cancer Hospital Care Center at Greenwich, Coastal Eye Surgeons, Greenwich Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Greenwich right now?
The largest active categories in Greenwich are Cancer & tumors (38), Eye & vision (5), Neurology & pain (1). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.